XNAS
INTS
Market cap7mUSD
Jul 08, Last price
0.29USD
1D
2.40%
1Q
-85.04%
IPO
-95.32%
Name
Intensity Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.20%
Rev. gr., 5y
%
Revenues
0k
Net income
-16m
L+54.37%
CFO
-15m
L+111.24%
Profile
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
IPO date
Jun 30, 2023
Employees
4
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 16,585 | 8,319 | 7,730 | |||
Unusual Expense (Income) | ||||||
NOPBT | (16,585) | (8,319) | (7,730) | |||
NOPBT Margin | ||||||
Operating Taxes | (132) | |||||
Tax Rate | ||||||
NOPAT | (16,585) | (8,319) | (7,598) | |||
Net income | (16,268) 54.37% | (10,538) 41.43% | (7,451) -5.60% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 3,232 | 22,425 | ||||
BB yield | -13.20% | -30.37% | ||||
| Debt | ||||||
Debt current | 28 | 40 | 4,492 | |||
Long-term debt | 248 | 296 | 143 | |||
Deferred revenue | ||||||
Other long-term liabilities | 36 | 10,036 | ||||
Net debt | (2,314) | (14,440) | 3,323 | |||
| Cash flow | ||||||
Cash from operating activities | (15,220) | (7,205) | (5,477) | |||
CAPEX | ||||||
Cash from investing activities | 6,354 | (6,023) | ||||
Cash from financing activities | 2,900 | 20,472 | 2,250 | |||
FCF | (16,560) | (9,203) | (6,543) | |||
| Balance | ||||||
Cash | 2,590 | 14,776 | 1,312 | |||
Long term investments | ||||||
Excess cash | 2,590 | 14,776 | 1,312 | |||
Stockholders' equity | (66,781) | (33,219) | (38,652) | |||
Invested Capital | 69,837 | 46,595 | 38,083 | |||
ROIC | ||||||
ROCE | 1,357.60% | |||||
| EV | ||||||
Common stock shares outstanding | 13,907 | 8,616 | 13,099 | |||
Price | 1.76 -79.46% | 8.57 | ||||
Market cap | 24,476 -66.85% | 73,842 | ||||
EV | 22,162 | 76,697 | ||||
EBITDA | (16,585) | (8,319) | (7,551) | |||
EV/EBITDA | ||||||
Interest | 305 | 82 | ||||
Interest/NOPBT | ||||||